Study Condition(s): Non-small Cell Lung Cancer

A Study of Necitumumab (LY3012211) and Abemaciclib (LY2835219) in Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Study Alias: JFCU

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02411591 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to evaluate the safety and efficacy of two new medicines, (Necitumumab and Abemaciclib), administered in combination in participants with advanced lung cancer (stage IV non-small-cell lung cancer).

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

You may continue participation in this study for as long as your study doctor determines that you are benefiting from the study treatment.
  • Participant must have a diagnosis of non-small cell lung cancer stage IV confirmed by histology or cytology:
    • Part A: non-small cell lung cancer stage IV (any type)
    • Part B: non-small cell lung cancer stage IV (squamous and nonsquamous)
  • Participant must have tumor tissue available for biomarker analyses
  • Participant must not be currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device. Prior treatment with CDK4/6-targeting agents or necitumumab is not permitted
  • Participant must not have undergone major surgery or received any investigational therapy in the 30-days prior to study enrollment
  • Participant must not have undergone chest irradiation within 4 weeks prior to receiving study treatment
  • Participant must not have brain metastases that are symptomatic
  • Female participant must not be pregnant or breastfeeding
  • Participant must not have a history of interstitial lung disease or an active non-infectious inflammation of the lung

Where to Participate

18 locations are currently available of 19 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.